Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Phase 1

Terminated

Conditions: Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
Recurrent B Acute Lymphoblastic Leukemia
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Refractory B Acute Lymphoblastic Leukemia
Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent B-Cell Non-Hodgkin Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma

Interventions: Biological: Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes
Drug: Cyclophosphamide
Drug: Fludarabine
Other: Laboratory Biomarker Analysis
Procedure: Leukapheresis
Other: Pharmacological Study

First Posted Date: 2017-04-07

Last Posted Date: 2024-04-10

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 55

Registration Number: NCT03103971

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Phase 2

Completed

Conditions: Follicular Lymphoma
Marginal Zone Lymphoma
Indolent Non-Hodgkin Lymphoma

Interventions: Biological: axicabtagene ciloleucel
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2017-04-07

Last Posted Date: 2025-01-06

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 159

Registration Number: NCT03105336

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

and more 16 locations

The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma

Phase 1

Conditions: B Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: CART-19

First Posted Date: 2017-04-05

Last Posted Date: 2017-04-05

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 30

Registration Number: NCT03101709

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma

Phase 2

Completed

Conditions: Acute Leukemia
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Langerhans Cell Histiocytosis
Acute Biphenotypic Leukemia
Acute Lymphoblastic Leukemia
Chronic Myelomonocytic Leukemia
Non-Hodgkin Lymphoma
Recurrent Hodgkin Lymphoma
Therapy-Related Myelodysplastic Syndrome
Acute Myeloid Leukemia

Interventions: Biological: Anti-Thymocyte Globulin
Drug: Busulfan
Drug: Clofarabine
Drug: Cyclophosphamide
Biological: Filgrastim-sndz
Drug: Fludarabine
Drug: Melphalan
Drug: Mycophenolate Mofetil
Biological: Rituximab
Drug: Tacrolimus
Radiation: Total-Body Irradiation
Procedure: Umbilical Cord Blood Transplantation

First Posted Date: 2017-03-30

Last Posted Date: 2023-10-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 6

Registration Number: NCT03096782

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma

Phase 1

Conditions: Multiple Myeloma

Interventions: Biological: Anti-BCMA CAR-T cells
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2017-03-28

Last Posted Date: 2019-02-27

Lead Sponsor: The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine

Target Recruit Count: 10

Registration Number: NCT03093168

Locations: 🇨🇳
Henan Province of TCM, Zhengzhou, Henan, China

CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer

Phase 1

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Biological: CART-PSMA-TGFβRDN cells
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2017-03-24

Last Posted Date: 2024-04-26

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 23

Registration Number: NCT03089203

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC)

Phase 1

Conditions: Hepatocellular Carcinoma

Interventions: Biological: Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2017-03-20

Last Posted Date: 2017-03-20

Lead Sponsor: Xinqiao Hospital of Chongqing

Target Recruit Count: 20

Registration Number: NCT03084380

Locations: 🇨🇳
Department of Oncology, Xinqiao Hospital, ChongQing, Chongqing, China

Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia

Phase 2

Terminated

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: Selinexor
Drug: Fludarabine
Drug: Cytarabine
Drug: methotrexate/hydrocortisone/cytarabine

First Posted Date: 2017-03-06

Last Posted Date: 2020-05-22

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 37

Registration Number: NCT03071276

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States

and more 4 locations

Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies

Phase 1

Completed

Conditions: Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Non-hodgkin Lymphoma
B-Lymphoid Malignancies

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Mesna
Biological: iC9/CAR.19/IL15-Transduced CB-NK Cells
Drug: AP1903

First Posted Date: 2017-02-17

Last Posted Date: 2024-03-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 49

Registration Number: NCT03056339

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

Phase 1

Completed

Conditions: Lymphoma, Extranodal NK-T-Cell
Enteropathy-Associated T-Cell Lymphoma
Lymphoma, Large B-Cell, Diffuse
Lymphoma, T-Cell, Peripheral
Lymphoma, Large-Cell, Anaplastic

Interventions: Biological: Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) T cells
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2017-02-10

Last Posted Date: 2023-01-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 26

Registration Number: NCT03049449

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy